JUN 02, 2016 9:58 AM PDT

A Concoction of Cells and Genes to Repair Damaged Heart Muscle

WRITTEN BY: Kara Marker
A heart attack creates a state of inadequate blood supply to organs and tissues that damages heart function and forms scar tissue for many weeks after the event. Using a pre-clinical heart attack model in mice, researchers from the University of Utah tested multiple combinations of stem cells, plasmid-based genes, and growth factors to see which concoctions created effective treatments for different conditions induced by a heart attack.

The researchers looked at three types of cells:
  • Umbilical cord-derived sub-epithelial cells (UC-SECs),
  • Bone marrow-derived mesenchymal stem cells (BM-MSCs),
  • Induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs),
two types of plasmid-based genes:
  • S100a1,
  • SDF-1a,
and a growth factor, VEGF165.

To mimic the biological and physiological aspects of heart muscle ischemia when the blood supply to the heart is obstructed as in during a heart attack, the researchers performed left anterior descending artery ligation on the mice models of disease. This technique is commonly used to imitate the impact of a heart attack on the body. With a single stich, researchers can tie off, or ligate, a blood vessel creating a state of inadequate blood supply to the heart that is almost immediately evident. After this procedure, the researchers could freely test different therapeutics to see what effect they had on the condition of the mice hearts.
 
The tissue-based cells were expanded under hypoxic conditions before injection, meaning they were deprived of adequate oxygen supply. The researchers injected each combination of cells, genes, and/or growth factor intramyocardially, and followed up at 4 and 12 weeks post-injection.
Intramyocardial Injection
After measuring, analyzing, and comparing measurements of echocardiography, hemodynamic catheterization measurements and histology throughout the study, the researchers saw several trends where certain therapeutic injections were best suited for correcting specific heart conditions that follow a heart attack.
 
First, UC-SECs appeared to be the best candidate for scar remodeling, but the two plasmid-based genes also proved to be better for scar remodeling than controls and other genes, cells, and growth factor combinations.
 
iPSC-CMs and S100a genes equally improved contractile function the best out of the samples tested, followed by UC-SECs. Lastly, angiogenesis, the creation of new blood vessels, was most successful when treated with VEGF165.
 
Study co-author Dr. Amit N. Patel said the study “demonstrated that, depending on which aspect of cardiac recovery is being evaluated, scar remodeling, improvement in contractile function, angiogenesis, or inflammation, a different [gene or cell] may be best suited.”
 
Indeed, this study provided background knowledge for further development of cellular and genetic therapies for preserving cardiac function. Presently, there is no approved therapy to address scar remodeling or replacement with fresh cardiomyocytes.
 
In conclusion, the researchers recommended that “further studies should aim to evaluate dose and combination therapies in order to decipher the most clinically applicable treatment.”
 
Their study was recently published in the journal Cell Transplantation.
 
 
Sources: Cell Transplantation Center of Excellence for Aging and Brain Repair, Journal of Visualized Experiments
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
DEC 09, 2020
Immunology
Antibodies as Warning Signs of a Silent Cardiovascular Killer
DEC 09, 2020
Antibodies as Warning Signs of a Silent Cardiovascular Killer
In atherosclerosis, cholesterol and other fatty deposits build up around the inner walls of an artery, creating a plaque ...
DEC 11, 2020
Cell & Molecular Biology
E-Cigarette Flavors Damage Heart Cells
DEC 11, 2020
E-Cigarette Flavors Damage Heart Cells
E-cigarettes or vapes were introduced a few years ago, and researchers are still trying to learn more about how they aff ...
DEC 29, 2020
Cardiology
Does Physical Activity Help Reduce the Risk of Aneurysms?
DEC 29, 2020
Does Physical Activity Help Reduce the Risk of Aneurysms?
An active lifestyle is a proven way to prevent many types of cardiovascular diseases. The increased blood flow can preve ...
MAR 29, 2021
Cardiology
Learning More About How Stress Breaks the Heart
MAR 29, 2021
Learning More About How Stress Breaks the Heart
Scientists are learning more about what causes a real phenomenon known as broken heart syndrome, or stress-related cardi ...
JUN 18, 2021
Drug Discovery & Development
FDA Approves First New Drug Since 2014 for Weight-loss
JUN 18, 2021
FDA Approves First New Drug Since 2014 for Weight-loss
A new medication called ‘Wegovy’ produced by Novo Nordisk has been approved by the Food and Drug Administrat ...
JUN 30, 2021
Clinical & Molecular DX
A Deep Learning Tool for Faster, Better Heart Disease Diagnoses
JUN 30, 2021
A Deep Learning Tool for Faster, Better Heart Disease Diagnoses
A new deep learning tool could help slash the time it takes to interpret cardiology scans to diagnose obstructive corona ...
Loading Comments...